Acebal Lucía J, Paez Borda A, Llorente Abarca C, Quijano Barroso P, Herrero Payo A, Bustamante Alarma S, Montes Díaz M J, Berenguer Sánchez A
Servicio de Urología, Hospital Universitario de Getafe, Madrid, España.
Arch Esp Urol. 1995 Jul-Aug;48(6):579-85.
The absence of tumor in up to 10% of cystectomy specimens of patients with invasive bladder cancer justify the search for non aggressive therapies. The present study attempts to establish the safety and curative capacity of TUR alone for patients with superficial muscle-infiltrating bladder cancer.
Over a period of 18 months, 12 patients with superficial muscle-infiltrating bladder cancer (T2) were diagnosed at our department, TUR was repeated in 9 of the 12 patients. The extension study was negative in all 9 patients.
The mean follow up was 12.8 months (range 7-70 months). Local recurrence was found in 4 patients (44.4%) who were submitted to another TUR; 3 were superficial and 1 invasive (with the same muscle involvement as at the initial diagnosis). The tumor-free survival rate was 9.3 months. No patient showed tumor progression.
The percentage and nature of local recurrence, tumor-free survival and the progression rate (which was not observed during the short follow up period) indicate that TUR is a treatment option that must be taken into account in selected patients with invasive bladder cancer.
在浸润性膀胱癌患者的膀胱切除标本中，高达10%的标本未发现肿瘤，这表明有必要寻找非侵袭性治疗方法。本研究试图确定单纯经尿道膀胱肿瘤切除术（TUR）对浅表性肌层浸润性膀胱癌患者的安全性和治疗效果。
在18个月的时间里，我们科室诊断出12例浅表性肌层浸润性膀胱癌（T2）患者，其中9例患者接受了重复TUR。所有9例患者的扩展检查均为阴性。
平均随访时间为12.8个月（范围7 - 70个月）。4例（44.4%）接受再次TUR的患者出现局部复发；3例为浅表性复发，1例为浸润性复发（与初始诊断时的肌层受累情况相同）。无瘤生存率为9.3个月。没有患者出现肿瘤进展。
局部复发的百分比和性质、无瘤生存率以及进展率（在短期随访期间未观察到）表明，TUR是部分浸润性膀胱癌患者必须考虑的一种治疗选择。
